<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02362711</url>
  </required_header>
  <id_info>
    <org_study_id>NPC-16-2</org_study_id>
    <nct_id>NCT02362711</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety, Long-Term Study of NPC-16 to Treat Dysmenorrhea</brief_title>
  <official_title>Phase3, Placebo Controlled, Randomized, Double-blinded, Long-Term, NSAID-Add-on, Clinical Trial of NPC-16 for Treatment of Dysmenorrhea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nobelpharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nobelpharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this long-term study is to determine whether NPC-16 is effective in the
      treatment of dysmenorrhea.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2015</start_date>
  <completion_date type="Actual">January 28, 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient Response to Treatment for Dysmenorrhea, as Evaluated by Total Dysmenorrhea Score</measure>
    <time_frame>52 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Response to Treatment for Dysmenorrhea, as Evaluated by Visual Analogue Scale (VAS) of Dysmenorrhea</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">248</enrollment>
  <condition>Dysmenorrhea</condition>
  <arm_group>
    <arm_group_label>NPC-16 Standard Dosing Regimen Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Levonorgestrel 0.09mg, Ethinylestradiol 0.02mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NPC-16 Continuous Dosing Regimen Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Levonorgestrel 0.09mg, Ethinylestradiol 0.02mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for NPC-16</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NPC-16 Standard Dosing Regimen Group</intervention_name>
    <arm_group_label>NPC-16 Standard Dosing Regimen Group</arm_group_label>
    <other_name>Levonorgestrel 0.09mg, Ethinylestradiol 0.02mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NPC-16 Continuous Dosing Regimen Group</intervention_name>
    <arm_group_label>NPC-16 Continuous Dosing Regimen Group</arm_group_label>
    <other_name>Levonorgestrel 0.09mg, Ethinylestradiol 0.02mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Group</intervention_name>
    <arm_group_label>Placebo Group</arm_group_label>
    <other_name>Placebo for NPC-16</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  dysmenorrhea

        Exclusion Criteria:

          -  severe hepatopathy

          -  pregnant woman
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tasuku Harada, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Tottori University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mikio Momoeda, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>St. Luke's International Hospital</affiliation>
  </overall_official>
  <verification_date>February 2015</verification_date>
  <study_first_submitted>February 9, 2015</study_first_submitted>
  <study_first_submitted_qc>February 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2015</study_first_posted>
  <last_update_submitted>April 14, 2019</last_update_submitted>
  <last_update_submitted_qc>April 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dysmenorrhea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levonorgestrel</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

